
X4 Pharmaceuticals announces FDA approval of its therapy, Xolremdi, for treating WHIM syndrome, a rare genetic immunodeficiency disease. WHIM, characterized by immune system dysfunction, affects less than 1,000 people in the U.S. Xolremdi, targeting the CXCR4 gene, showed a 60% reduction in infection rate in late-stage trials. The approval grants X4 a rare pediatric disease priority review voucher. Xolremdi's mechanism mobilizes white blood cells, enhancing immune function. Besides WHIM syndrome, Xolremdi is under evaluation for treating chronic disorders with low neutrophil levels.
Like
Save
Share